Oragenics (NYSEAMERICAN:OGEN) Stock Picked Up by Analysts at Ascendiant Capital Markets

Equities research analysts at Ascendiant Capital Markets began coverage on shares of Oragenics (NYSEAMERICAN:OGEN – Get Free Report) in a research note issued to investors on Wednesday, Zacks reports. The brokerage set a “moderate buy” rating on the stock.

Oragenics Price Performance

OGEN stock opened at $0.17 on Wednesday. Oragenics has a 1-year low of $0.13 and a 1-year high of $1.11. The business has a fifty day moving average price of $0.41 and a 200-day moving average price of $0.57. The stock has a market capitalization of $775,720.00, a P/E ratio of -0.01 and a beta of 1.28.

Oragenics (NYSEAMERICAN:OGEN – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.58) earnings per share (EPS) for the quarter.

Oragenics Company Profile

(Get Free Report)

Oragenics is a biotechnology company developing intranasal drug candidates for neurological conditions. Its lead program, ONP-002, is an investigational treatment for concussion, also known as mild traumatic brain injury. The company is studying the candidate’s potential to reach the brain through nasal delivery; it is not an approved treatment. Oragenics previously focused on oral health and infectious-disease programs, including probiotics and lantibiotics, a class of antimicrobial compounds. The company later shifted its focus toward neurological disorders and obtained rights to develop ONP-002.

See Also

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.